Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re: Some here are our worst enemy:/ Ease
4
Sep 23, 2009 11:32AM

Data provided by Capital IQ, except where noted. based on .25 PPS

VALUATION MEASURES
Market Cap (intraday)5: 102.53M
Enterprise Value (23-Sep-09)3: 115.76M
Trailing P/E (ttm, intraday): 124.95
Forward P/E (fye 31-May-11) 1: N/A
PEG Ratio (5 yr expected): N/A
Price/Sales (ttm): 22.22
Price/Book (mrq): 4.03
Enterprise Value/Revenue (ttm)3: 21.62
Enterprise Value/EBITDA (ttm)3: -19.372
FINANCIAL HIGHLIGHTS
Fiscal Year
Fiscal Year Ends: 31-May
Most Recent Quarter (mrq): 31-May-09
Profitability
Profit Margin (ttm): 16.46%
Operating Margin (ttm): -125.29%
Management Effectiveness
Return on Assets (ttm): -14.18%
Return on Equity (ttm): 3.33%
Income Statement
Revenue (ttm): 5.35M
Revenue Per Share (ttm): 0.013
Qtrly Revenue Growth (yoy): -50.60%
Gross Profit (ttm): 2.27M
EBITDA (ttm): -5.98M
Net Income Avl to Common (ttm): 881.51K
Diluted EPS (ttm): 0.002
Qtrly Earnings Growth (yoy): -96.50%
Balance Sheet
Total Cash (mrq): 6.27M
Total Cash Per Share (mrq): 0.015
Total Debt (mrq): 3.04M
Total Debt/Equity (mrq): N/A
Current Ratio (mrq): 7.796
Book Value Per Share (mrq): 0.072
Cash Flow Statement
Operating Cash Flow (ttm): -7.17M
Levered Free Cash Flow (ttm): -2.13M
Share
New Message
Please login to post a reply